KORU Medical Q3 revenue rises 11% year-over-year
Overview
U.S. medical device maker's Q3 revenue rose 11% yr/yr to $11.6 mln
Company posted second straight quarter of positive net income and adjusted EBITDA
Company raised full-year 2026 revenue guidance to $48.0-$48.5 mln
Outlook
KORU Medical raises 2026 revenue guidance to $48.0-$48.5 mln from $47.5-$48.5 mln
Company now sees 2026 gross margin at 63-64%, up from prior 62-64% range
Company raises year-end 2026 cash balance forecast to over $8.0 mln
Result Drivers
DOMESTIC GROWTH - Higher pump and consumable volumes, new patient starts, and market share gains drove domestic revenue increase
MARGIN IMPROVEMENT - Gross margin rose due to lower manufacturing costs, favorable customer mix, and tariff rebates
INTERNATIONAL VARIATION - International revenue declined due to a strong prior-year comparison, partly offset by new patient starts
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | $218,000 | ||
Q3 Gross Margin | 65.2% | ||
Q3 Operating Expenses | $7.36 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for KORU Medical Systems Inc is $6.00, about 85.8% above its November 9 closing price of $3.23
The stock recently traded at 304 times the next 12-month earnings vs. a P/E of 28,848 three months ago
Reuters Recommended Reads
Nov 9 - Myomo Q3 revenue rises 22% to record high
Nov 10 - LENSAR Q3 revenue slightly misses estimates on slower surgical scheduling
Nov 9 - OraSure Technologies Q3 revenue rises, gross margin improves
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)